Cargando…
From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia
BACKGROUND: The World Health Organization (WHO) recommends consideration of mass drug administration (MDA) for malaria control in low-endemic settings approaching elimination. However, MDA remains a controversial strategy, as multiple individual, social, and operational factors have shown to affect...
Autores principales: | Fehr, Alexandra, Nieto-Sanchez, Claudia, Muela, Joan, Jaiteh, Fatou, Ceesay, Omar, Maneh, Ebrima, Baldeh, Dullo, Achan, Jane, Dabira, Edgard, Conteh, Bakary, Bunders-Aelen, Joske, Smekens, Tom, Broekhuizen, Henk, D’Alessandro, Umberto, Peeters Grietens, Koen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073909/ https://www.ncbi.nlm.nih.gov/pubmed/33902611 http://dx.doi.org/10.1186/s12936-021-03732-z |
Ejemplares similares
-
Doing ‘reciprocity work’: The role of fieldworkers in a mass drug administration trial in the Gambia
por: Fehr, Alexandra, et al.
Publicado: (2022) -
Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial
por: Dabira, Edgard Diniba, et al.
Publicado: (2020) -
Reactive, self-administered malaria treatment against asymptomatic malaria infection: results of a cluster randomized controlled trial in The Gambia
por: Okebe, Joseph, et al.
Publicado: (2021) -
Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial
por: Soumare, Harouna M., et al.
Publicado: (2022) -
Costs and barriers faced by households seeking malaria treatment in the Upper River Region, The Gambia
por: Broekhuizen, Henk, et al.
Publicado: (2021)